Want to take quizzes and track your credits?
Widespread availability of commercial assays that detect anti–severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies has enabled researchers to examine naturally acquired immunity to coronavirus disease 2019 (COVID-19) at the population level. Several studies have found that the SARS-CoV-2 seroprevalence (the percentage of the population with serum containing antibodies that recognize the virus) has remained below 20% even in the most adversely affected areas globally, such as Spain and Italy.1- 3 In this issue of JAMA Internal Medicine, Bajema et al4 contribute new information on the shifting nature of SARS-CoV-2 seroprevalence in the US. The study uses national data to expand on an earlier US Centers for Disease Control and Prevention study of seroprevalence of antibodies to SARS-CoV-2 in 10 US sites.3
Sign in to take quiz and track your certificates
JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 CME Credit™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC
CME Disclosure Statement: Unless noted, all individuals in control of content reported no relevant financial relationships. If applicable, all relevant financial relationships have been mitigated.
Corresponding Author: Brad Spellberg, MD, 2051 Marengo Street, Los Angeles, CA 90033 (firstname.lastname@example.org).
Published Online: November 24, 2020. doi:10.1001/jamainternmed.2020.7986
Conflict of Interest Disclosures: Dr Spellberg reported personal fees from IQVIA and service on multiple data safety monitoring boards for therapeutics for COVID-19, with no financial interest in the sponsors, products, or outcomes of the trials during the conduct of the study. No other disclosures were reported.
You currently have no searches saved.
You currently have no courses saved.